Table of Contents
<< Previous Issue | Jun 2013 (Vol: 2013, Issue: 6) | Next Issue >> |
- Section: Joint Venture
-
Amgen to Re-Enter Japanese Market with Astellas Pharma Partnership
- Section: Mergers & Acquisitions
-
Elan Strikes Series of Deals to Diversify and Stave Off Royalty Pharma
-
Novo A/S Acquires Anti-Infectives Developer Xellia Pharmaceuticals from 3i
-
BTG Expands Interventional Medicine Business with Acquisitions of Ekos and Nordion’s Targeted Therapies Division
-
Valeant Aims to Compete in Ophthalmology with US$8.7 B Bausch & Lomb Buyout
-
AstraZeneca Bolsters Late-Stage Cardiovascular Disease Pipeline with Omthera Pharmaceuticals Purchase
-
GSK Brings Next-Generation Vaccine Technology In-House with Okairos Acquisition
- Section: Research & Development
-
Pfizer Looks to Next-Generation Antibody-Drug Conjugates with CytomX Therapeutics Collaboration
-
J&J’s Janssen Biotech Invests in Microbiome Research with Second Genome Collaboration